Want to see FTH full AI Analyst Report?
FTH Stock Chart & Stats
$32.97
-$0.03(-5.03%)
At close: 4:00 PM EST
$32.97
-$0.03(-5.03%)
Day’s Range― - ―
52-Week Range$7.45 - $42.14
Previous CloseN/A
VolumeN/A
Average Volume (3M)286.33K
Market Cap
$1.01B
Enterprise Value-$38.00
Total Cash (Recent Filing)$186.44M
Total Debt (Recent Filing)$592.00K
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 10, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-141.65
Shares Outstanding25,840,425
10 Day Avg. Volume242,416
30 Day Avg. Volume286,331
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$56.11Price Target Upside70.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-14.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives Faeth greater financial flexibility while it develops its oncology pipeline. A modest debt burden reduces solvency pressure and interest obligations, helping preserve strategic options even though the company has not yet demonstrated sustainable earnings.
Improving Cash-burn TrendThe smaller latest-TTM free-cash-flow outflow indicates some improvement in the pace of cash consumption. If sustained, this could extend the company’s operating runway and make capital planning more manageable, although the business remains cash-burning rather than self-funding.
Performance-linked IncentivesThe performance-based option structure ties employee and leadership rewards to a demanding long-term outcome rather than routine service alone. This can improve alignment around shareholder value creation and strategic execution, while strict forfeiture terms limit rewards without success.
Bears Say
No Revenue TractionThe absence of meaningful revenue across multiple annual periods shows that Faeth remains a development-stage biotech without a commercial earnings base. Continued sizable losses leave future value dependent on successful pipeline advancement and eventual commercialization rather than established demand.
Persistent Cash BurnPersistent negative operating and free cash flow means Faeth cannot currently fund research and operations from internally generated cash. Ongoing capital needs may constrain strategic flexibility and expose the company to financing dependence if losses continue over the next several quarters.
Dilution RiskThe ATM program provides financing capacity but creates a durable risk of shareholder dilution when shares are issued. The large preferred-stock conversion has already expanded the common share base, while future fundraising could further reduce existing ownership percentages.
Faeth Therapeutics News
FTH FAQ
What was Faeth Therapeutics’s price range in the past 12 months?
Faeth Therapeutics lowest stock price was $7.45 and its highest was $42.14 in the past 12 months.
What is Faeth Therapeutics’s market cap?
Faeth Therapeutics’s market cap is $1.01B.
When is Faeth Therapeutics’s upcoming earnings report date?
Faeth Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 58 days.
How were Faeth Therapeutics’s earnings last quarter?
Faeth Therapeutics released its earnings results on Aug 04, 2026. The company reported -$2.84 earnings per share for the quarter, missing the consensus estimate of -$2.636 by -$0.204.
Is Faeth Therapeutics overvalued?
According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued.
Does Faeth Therapeutics pay dividends?
Faeth Therapeutics does not currently pay dividends.
What is Faeth Therapeutics’s EPS estimate?
Faeth Therapeutics’s EPS estimate is -0.79.
How many shares outstanding does Faeth Therapeutics have?
Faeth Therapeutics has 25,840,425 shares outstanding.
What happened to Faeth Therapeutics’s price movement after its last earnings report?
Faeth Therapeutics reported an EPS of -$2.84 in its last earnings report, missing expectations of -$2.636. Following the earnings report the stock price went down -6.73%.
Which hedge fund is a major shareholder of Faeth Therapeutics?
Currently, no hedge funds are holding shares in FTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faeth Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.11 (70.19% Upside)
$56.11 (70.19% Upside)
Blogger Sentiment
Bullish
FTH Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
300.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
495.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
FTH Stock 12 Month Forecast
Average Price Target
$56.11
▲(70.19% Upside)
Technical Analysis
Cellectar Biosciences
―
Cocrystal Pharma
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Ownership Overview
5.14% Insiders
0.26% Mutual Funds
46.62% Other Institutional Investors
47.92% Public Companies and
Individual Investors